<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609711</url>
  </required_header>
  <id_info>
    <org_study_id>AGCA_DI_1501</org_study_id>
    <nct_id>NCT02609711</nct_id>
  </id_info>
  <brief_title>Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <brief_summary>
    <textblock>
      primary object : Evaluate pharmacokinetic drug-drug interaction of Candesartan and
      Atorvastatin
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Candesartan cilexetil)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Atorvastatin)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.333, 1.667, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (Candesartan cilexetil)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (Atorvastatin)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.333, 1.667, 2, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Male Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <other_name>atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy males 20 to 45 years at screening.

          -  BMI 18-29 kg/m2

        Exclusion Criteria:

          -  History of cardiovascular, respiratory, hepatic, renal, neuropsychiatric, endocrine,
             hematologic disease

          -  Hypersensitivity reactions to drugs or significant hypersensitivity reactions in the
             history of Candesartan and Atorvastatin

          -  Hypotension (DBP ≤ 100 mmHg or SBP ≤ 95mmHg) and hypertension (SBP ≥ 150 mmHg or DBP ≥
             95 mmHg)

          -  Gastrointestinal disease affected the absorption of medications

          -  Genetic disease of Galactose intolerance, Lapp lactose deficiency or glucose-galactose
             malabsorption

          -  AST or ALT &gt; 2 x normal range

          -  Total bilirubin &gt; 2.0 mg/dl

          -  CK &gt; 2 x normal range

          -  eGFR &lt; 60 mL/min/1.73m2

          -  Subject who have drunken habitually (alcohol more than 21 units/week, 1 unit = 10 g =
             12.5 mL of pure alcohol) or who are unable to quit drinking during this study

          -  Subject who have smoke habitually more than 10 cigarettes/day or who are unable to
             quit smoking during this study

          -  Subject who treated with any investigational drugs within 90 days before the
             administration of investigational drug

          -  Previously donate whole blood within 60 days or component blood within 30 days or
             transfusion within 30 days

          -  Subject who treated with any drug within 30 days can affect absorption, distribution,
             metabolism, excretion of candesartan or atorvastatin

          -  Subject who treated with any Rx only drug or herbal drug within 14 days and any OTC
             within 7 days

          -  History of drug abuse

          -  Genetic neuromuscular disorder or family history of neuromuscular disorder

          -  Unusual diet affected the absorption, distribution, metabolism, excretion of
             medications

          -  Subjects deemed ineligible by investigator based on other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul Woo Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>INHA UNIV. HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha Univ. Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

